AOD-9604 — 5mg (Canada)

AOD-9604 — 5mg (Canada)

Injectable research peptide. Harmova does not promise fat loss, muscle gain, or any disease outcome. Use only under qualified supervision where legal.

Background

AOD-9604 emerged from academic work in Australia that asked whether the fat-metabolism signals linked to growth hormone could be isolated from the broader anabolic and glycemic effects of intact GH. The result is a small modified fragment—often discussed alongside the C-terminal region of the GH sequence—designed as a research tool rather than a copy of full-length hormone.

Adipose metabolism (preclinical and early human narratives)

Laboratory writing often frames AOD-9604 around two paired ideas: encouraging fat release (lipolysis) and dampening the conversion of surplus substrate into new stored fat (lipogenesis). Authors contrast this with unmodified GH, which carries wider endocrine baggage in both animal and human contexts.

Cell-culture work with human fat tissue has reported differential responses between obese-derived and lean-derived adipocytes—interpreted cautiously in reviews—together with interest in how fuel oxidation and handling change under peptide exposure.

Animal pharmacology

Rodent obesity models have been used to probe oral or systemic dosing, body-weight trajectories, lipolytic enzyme activity in fat pads, and insulin-sensitivity readouts compared with vehicle or, in some papers, chronic GH. Authors generally highlight a favorable metabolic profile in those models while stressing species and design limits.

Beyond adipose tissue (research directions)

Published agendas also mention cartilage and bone biology, osteoarthritis models, lipid panels, and HIV-related fat-redistribution syndromes—as investigational threads only, not labeled indications on this storefront.

Academic–industry bone and matrix work

Canadian hospital–affiliated groups have reported in vitro and animal data on mineralized tissue, chondrocyte behavior, and fracture-healing models in partnership with the peptide’s historical patent holder. Those programs are framed as proof-of-concept for repair settings, not as instructions for self-treatment.

Combination and regeneration studies

Independent animal experiments have combined AOD-9604 with hyaluronic-acid–style matrices to score cartilage morphology, and cell-culture papers discuss stem-cell lineage and matrix protein output. All remain preclinical; human cartilage benefit is unproven here.

Oncology and drug-delivery lab science

Cell-line and nanoparticle papers ask whether certain GH fragments alter how chemotherapy drugs associate with tumor-cell proteins in dishes. That is basic research only—not evidence that this vial treats or prevents cancer, and not a reason to use AOD-9604 outside a regulated protocol.

Compliance

Marketing phrases like “fat burner” or “melts fat” are avoided on purpose. Outcomes depend on diet, activity, genetics, and medical context. Dose, route (injection versus other delivery discussed in papers), and monitoring belong to your clinician and the official label.